GlobeNewswire

NRT Acquires OfferCraft, Award-Winning Provider of Artificial Intelligence, Gamification and Digital Content Solutions

Dela

Acquisition of hyper-engagement platform enhances NRT's ability to deliver transformative, revenue-generating technology to its customers

LAS VEGAS, March 20, 2018 (GLOBE NEWSWIRE) -- NRT Technology Corp. ("NRT"), a leading provider of digital commerce experiences in gaming and financial services, announced that it has acquired the assets of privately held OfferCraft, a software company that uses artificial intelligence and gamification to drive loyalty, engagement and revenue. Terms of the agreement are not disclosed.

The deal will allow NRT to integrate OfferCraft's patent-pending solutions into its existing kiosk, mobile, table games and cashless payment product lines, while also expanding into entirely new areas across nearly every digital channel.

OfferCraft's artificial intelligence software allows offers, coupons and rewards to be distributed digitally across email, SMS, websites, social media, kiosks, the Point of Sale, signage, and more. Unlike traditional marketing content, these incentives can change themselves into something different if they're initially ignored.

For example, if a customer receives a 30% discount but doesn't use it, that incentive will evolve into something different and can automatically send a text message, email or push notification to the patron with the new alternative. Customers can redeem their personalized offer directly at a kiosk, a POS terminal, or another system using a unique code on their phone, similar to using your phone to check in for a flight. Everything is tracked, A/B-tested and optimized in real time to continually increase conversion rates, while slashing printing costs and fraud.

OfferCraft's gamification platform builds on its AI tools to enable a wide range of marketing and HR content to be presented in the form of fun, exciting games that are more likely to be clicked, remembered and redeemed - further increasing profitability.

John Dominelli, Founder and CEO of NRT, said: "The OfferCraft platform is already being used by customers in the US, Canada, South America, Africa, and Australia. Adding these fun, digital experiences to almost any kind of marketing generates higher engagement and stronger bottom line results. We believe our partners are going to be blown away once they see this technology in action."

The acquisition of OfferCraft's assets follows NRT's recent acquisitions of eMarker and VisuaLimits, its strategic investment in Gaming Analytics, and its pending merger with Sightline Payments ("Sightline").  Following receipt of all required gaming approvals, NRT and Sightline will combine to become NRT Sightline. 

"OfferCraft is not only an impressive platform, there is a clear synergy in the culture and product vision between the leadership of the two companies," said Kirk Sanford, Sightline's Founder and CEO. "Casinos are racing to keep up with the digital economy, and this transaction will allow us to incorporate gamification and artificial intelligence into the Play+ cashless gaming experience that allows patrons to pay for their play without cash, the cutting-edge mobile applications we're delivering with market leader Kony, and our Habit Analytics platform that uncovers powerful insights about player behavior."

The entire OfferCraft team will immediately become part of NRT, and will form NRT's new Interactive division. Aron Ezra, CEO of OfferCraft, will take on the newly created role of Chief Digital Officer at NRT, where he will oversee the OfferCraft product, the NRT mobile app platform strategy, and several soon-to-be-announced initiatives that will advance the company's mission to connect the guest experience.

"Our team couldn't be more excited about joining the NRT family," said Ezra. "We have grown exponentially in the past several years, and we wanted to align ourselves with a forward-thinking group that genuinely cares about its customers. We found that with NRT - joining forces means we'll be able to innovate faster than ever before to deliver groundbreaking innovations that our clients will love."

About NRT & Sightline

On closing of the pending merger, NRT Sightline will be the global leader in the design and development of enterprise platforms for the gaming industry. Every year NRT and Sightline enable more than 1 billion physical and digital commerce experiences at over 600 casino properties worldwide.  By seamlessly combining technological innovation with strategic partnerships, our companies create the most convenient, reliable, and secure omni-channel payment ecosystem for casino operators and their guests. NRT and Sightline have been recognized with numerous industry awards, including the coveted "Most Innovative Gaming Technology Product of the Year" for our Play+(TM) cloud-based cashless funding platform. Our collective solutions are used by casinos, lotteries, race and sports, banking & retailers around the world. We operate across 7 countries and have corporate offices in Las Vegas, Toronto, Macau, and Singapore.

For further information about this acquisition, please contact:  Michael Dominelli, NRT's SVP Marketing  mdominelli@nrttech.com

For more information about Sightline or its pending merger with NRT, please contact:  Omer Sattar, Sightline's EVP Strategic Relationships osattar@sightlinepayments.com

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NRT Sightline via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum